Cerdulatinib

Research use only, not for human use.

Cerdulatinib is an novel oral dual Syk/JAK inhibitor.

Cerdulatinib, also known as PRT2070 and PRT062070, is a n ovel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. Cerdulatinib preferentially inhibited JAK1 and JAK3 dependent cytokine mediated signaling and functional responses in various cell types. IL2 mediated STAT5 Y694 was inhibited with an IC50 of 0.27μM, while IL4 mediated signaling to STAT6 Y641 and functional responses in B cells and monocytes, namely CD69, CD25, and CD23 up-regulation, were inhibited with IC50’s within the range of 0.11μM to 0.57μM. It is currently being studied in patients with genetically-defined hematologic cancers, as well as for patients who have failed therapy due to relapse or acquired mutations.

PRT2070;PRT-062070; Cerdulatinib

Others

Other Targets

JAK1; JAKs; Syk

Cancer

——

1198300-79-6

445.54

C20H27N7O3S

98%

DMSO : ≥ 30 mg/mL; 67.33 mM

CCS(=O)(=O)N1CCN(CC1)c1ccc(cc1)Nc1ncc(C(=O)N)c(NC2CC2)n1

4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide

(-20℃)

With Ice Pack

≥ 2 years